SIMCERE PHARMA(02096): Enze Shu has been approved by the National Medical Products Administration to be launched in China.

SIMCERE PHARMA (02096) announced that on July 3, 2025, a new class of biological drug Enzeshu (bevacizumab injection) has been approved by the National Medical Products Administration (NMPA) in China for marketing (Approval number: S20250037, Approval date: June 30, 2025). Enzeshu combined with paclitaxel, liposomal doxorubicin, or topotecan is used for the treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have received no more than one prior systemic therapy for platinum-resistant disease. There is currently no approval for anti-angiogenic therapy for platinum-resistant ovarian cancer (PROC) in China, especially for patients who have previously received anti-angiogenic therapy, there is a great unmet clinical need. The approval of Enzeshu will provide a much-needed new treatment option for patients with platinum-resistant ovarian cancer in China.